Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BAY1905254 |
| Synonyms | |
| Therapy Description |
BAY1905254 is an antibody that specifically binds to and inhibits the immunosuppressive activity of ILDR2, potentially resulting in improved anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2778, PMID: 32312711). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BAY1905254 | BAY 1905254|BAY-1905254 | BAY1905254 is an antibody that specifically binds to and inhibits the immunosuppressive activity of ILDR2, potentially resulting in improved anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2778, PMID: 32312711). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03666273 | Phase I | BAY1905254 BAY1905254 + Pembrolizumab | A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 | Completed | USA | 0 |